Aurinia Pharmaceuticals Inc.

AUPH · NasdaqGM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders6.6%

Institutions60.5%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$283.06M	$235.13M	$175.51M	$134.03M	$45.60M	$50.12M
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	$32.66M	$28.25M	$14.15M	$5.66M	$1.09M	–
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	$104.91M	-$4.69M	-$91.69M	-$111.47M	-$180.74M	-$104.29M
Operating income as a percentage of revenue.	37.1%	-2.0%	-52.2%	-83.2%	-396.3%	-208.1%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	$287.20M	$5.75M	-$78.02M	-$108.18M	-$180.97M	-$102.68M
Net income divided by the number of shares outstanding — profit attributable to each share.	$2.14	$0.04	$-0.54	$-0.76	$-1.40	$-0.87
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$2.07	$0.04	$-0.54	$-0.76	$-1.40	–

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$80.21M	$83.43M	$48.90M	$94.20M	$231.90M	$272.35M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$751.59M	$550.64M	$548.06M	$470.86M	$543.37M	–
Everything the company owes — debt, unpaid bills, and other obligations.	$170.26M	$173.17M	$170.11M	$65.42M	$64.28M	–
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$581.33M	$377.48M	$377.95M	$405.44M	$479.09M	–

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	$135.66M	$44.39M	-$33.46M	-$79.53M	-$157.69M	-$69.86M

2025-12-31

2024-12-31

2023-12-31

2022-12-31

2021-12-31

2020-12-31

Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.

$135.66M

$44.39M

-$33.46M

-$79.53M

-$157.69M

-$69.86M

	You	Peer avg
P/E	7.1	6.5
Revenue Growth	+18.9%	-90.6%
ROE	66.1%	-23.3%

Aurinia Pharmaceuticals Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison